ERGO is part of the EURION Cluster of eight research projects from the Call ‘New Testing and Screening Methods to Identify Endocrine Disrupting Chemicals’. Funded by the EU Horizon 2020 Research and Innovation Programme, this is the largest public funding of this type of research in Europe. The eight projects, funded by €50 million and consisting of more than 70 research groups, are focusing on improved and harmonised methods as well as screening and testing strategies for the less-studied endocrine disruptor related outcomes, such as metabolic diseases, thyroid hormone disruption, female reproduction and developmental neurotoxicity. EURION, guided by a common international advisory panel, has been formed to optimise synergies and avoid overlaps between the eight projects. EURION will work together towards the common goal by means of working groups, workshops and meetings as well as data sharing and overall tight collaboration.
ATHENA
Assays for the identification of Thyroid Hormone axis-disrupting chemicals: Elaborating Novel Assessment strategies
EDCMET
Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways
ENDPOINTS
Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental NeuroToxicity
ERGO
Breaking down the wall between human health and environmental testing of endocrine disrupting chemicals: EndocRine Guideline Optimisation
FREIA
Female Reproductive toxicity of EDCs: a human evidence-based screening and Identification Approach
GOLIATH
Generation Of Novel, Integrated and Internationally Harmonised Approaches for Testing Metabolism Disrupting Compounds
OBERON
An integrative strategy of testing systems for identification of Endocrine Disrupters related to metabolic disorders
SCREENED
A multistage model of thyroid gland function for screening endocrine disrupting chemicals in a biologically sex-specific manner